PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
14 May 2008 Board of Directors
443 994 0101
2 NEW PLUROGEL™ PRODUCTS INTRODUCED
AT THE EUROPEAN WOUND MANAGEMENT CONGRESS (EWMA) IN LISBON
(Charlottesville, VA, May 14, 2008) – 2 new products incorporating PluroGen’s core gel technology, PluroGel™,
were introduced at Europe’s premiere wound healing congress, the EWMA, held for 2008 on 14 - 16 May in
Lisbon, Portugal. PluroGen’s partner for these products, Welcare Industries, S.p.A., introduced both EasyDerm®
Chronic Wound with PluroGel™ and EasyDerm® BFR (Bacterial Film Remover) with PluroGel™. Both products
received strong interest at the Welcare booth in the EWMA exhibition hall where they were presented.
Commenting on the product launch, Neal G. Koller, President & CEO of PluroGen, said, “This is a milestone event
for PluroGen because it is the first commercial product launch in the company’s history. Welcare has done a
terrific job in the launch, generating solid interest in their products with our PluroGel™ from doctors, nurses and
distributors attending the EWMA. PluroGen has taken a major and important step forward.”
Fulvia Lazzarotto, Managing Director for Welcare, stated, “The doctors and nurses, and our distributors, visiting
our launch at the EWMA had great interest in our new EasyDerm® products with PluroGel™. EasyDerm® Chronic
Wound with PluroGel™ addresses the needs of a critical step in wound therapy, specifically wound cleansing,
where there is a need for an improved product. EasyDerm® BFR with PluroGel™ provides an answer to the
growing concern for MRSA and VRE. This was an important product launch for Welcare. We have high
expectations for our new EasyDerm® with PluroGel™ products.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its four patent-protected technology platforms. The
Company’s core gel technology provides superior and differentiated physical and bio-active benefits to wound
healing. The technology is configurable to deliver drug and non-drug compounds as protected and advanced
therapeutic products for simple and complex wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain,
inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially as a component in skin and wound cleansing products, as
topical barrier product, and, for two branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and
PluroGel™ TAG. PluroGel™ TAG is currently in routine use at the University of Virginia Medical Center, having
shown superior results on more than 2,000 patients in two different patient populations, severe burns and
chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and in the
life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing, distribution
and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and total patient
cleansing products, clinical and patient protection products and specialty procedure products. Welcare is
currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or Welcare Industries, S.p.a website is not
incorporated herein by reference or otherwise.
President & CEO
14 May 2008 Board of Directors
443 994 0101
2 NEW PLUROGEL™ PRODUCTS INTRODUCED
AT THE EUROPEAN WOUND MANAGEMENT CONGRESS (EWMA) IN LISBON
(Charlottesville, VA, May 14, 2008) – 2 new products incorporating PluroGen’s core gel technology, PluroGel™,
were introduced at Europe’s premiere wound healing congress, the EWMA, held for 2008 on 14 - 16 May in
Lisbon, Portugal. PluroGen’s partner for these products, Welcare Industries, S.p.A., introduced both EasyDerm®
Chronic Wound with PluroGel™ and EasyDerm® BFR (Bacterial Film Remover) with PluroGel™. Both products
received strong interest at the Welcare booth in the EWMA exhibition hall where they were presented.
Commenting on the product launch, Neal G. Koller, President & CEO of PluroGen, said, “This is a milestone event
for PluroGen because it is the first commercial product launch in the company’s history. Welcare has done a
terrific job in the launch, generating solid interest in their products with our PluroGel™ from doctors, nurses and
distributors attending the EWMA. PluroGen has taken a major and important step forward.”
Fulvia Lazzarotto, Managing Director for Welcare, stated, “The doctors and nurses, and our distributors, visiting
our launch at the EWMA had great interest in our new EasyDerm® products with PluroGel™. EasyDerm® Chronic
Wound with PluroGel™ addresses the needs of a critical step in wound therapy, specifically wound cleansing,
where there is a need for an improved product. EasyDerm® BFR with PluroGel™ provides an answer to the
growing concern for MRSA and VRE. This was an important product launch for Welcare. We have high
expectations for our new EasyDerm® with PluroGel™ products.”
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its four patent-protected technology platforms. The
Company’s core gel technology provides superior and differentiated physical and bio-active benefits to wound
healing. The technology is configurable to deliver drug and non-drug compounds as protected and advanced
therapeutic products for simple and complex wound healing. PluroGen’s product pipeline targets improved,
protected therapies for the 6 Areas of Therapeutic Treatment of tissue healing (cleansing, infection, pain,
inflammation, tissue salvage, tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially as a component in skin and wound cleansing products, as
topical barrier product, and, for two branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and
PluroGel™ TAG. PluroGel™ TAG is currently in routine use at the University of Virginia Medical Center, having
shown superior results on more than 2,000 patients in two different patient populations, severe burns and
chronic wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and in the
life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing, distribution
and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and total patient
cleansing products, clinical and patient protection products and specialty procedure products. Welcare is
currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and
which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange
Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or Welcare Industries, S.p.a website is not
incorporated herein by reference or otherwise.
| EasyDerm® BFR with PluroGel™ |
| EasyDerm® Chronic Wound with PluroGel™ |
| Welcare Exhibit Booth at EWMA 2008 14 -16 May, Lisbon, Portugal |
